eligibility_summary
Eligible: adults 18–75 with histologically confirmed CD20+ follicular lymphoma grade 1–3a, untreated, meeting GELF, stage II–IV, ECOG 0–2, intermediate–high FLIPI, adequate marrow/renal/hepatic function, life expectancy ≥6 mo, contraception/consent required. Exclude: CNS or transformed disease, grade 3b, recent other malignancy, active HIV/HBV/HCV/serious infection, significant cardiac (LVEF<50%), neuropathy ≥2, ILD/pneumonia, serious neuro/psych disorders.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm frontline study in untreated intermediate–high risk follicular lymphoma testing: Zanubrutinib (small-molecule Bruton’s tyrosine kinase [BTK] inhibitor) to block B‑cell receptor signaling, Obinutuzumab (type II anti‑CD20 monoclonal antibody, glycoengineered) to deplete CD20+ B cells via enhanced ADCC, CDC, and direct apoptosis, CHOP chemotherapy—Cyclophosphamide (alkylator/DNA crosslinking), Doxorubicin (anthracycline/topoisomerase II inhibition/ROS), Vincristine (vinca alkaloid/microtubule disruption), Prednisone (glucocorticoid, lympholytic). Induction: Zanubrutinib+G‑CHOP (4–6 cycles), maintenance: Zanubrutinib+Obinutuzumab (1 year). Targets: malignant CD20+ B cells, BCR/BTK pathway, DNA replication/repair, microtubules, immune effector pathways (ADCC/CDC).